Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke - Way to endeavor

被引:33
作者
Huang, Poyin [1 ]
Chen, Chun-Hung [1 ]
Yang, Yuan-Han [1 ]
Lin, Ruey-Tay [1 ]
Lin, Feng-Cheng [1 ]
Liu, Ching-Kuan [1 ]
机构
[1] Kaohsiung Med Univ, Chung Ho Mem Hosp 100, Dept Neurol, Kaohsiung 807, Taiwan
关键词
eligibility; stroke; tissue plasminogen activator; stroke code;
D O I
10.1159/000094994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h. Methods: A strict protocol for hyper-acute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68). Conclusion: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 19 条
[1]   Hyperdense middle cerebral artery sign: Can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? [J].
Agarwal, P ;
Kumar, S ;
Hariharan, S ;
Eshkar, N ;
Verro, P ;
Cohen, B ;
Sen, S .
CEREBROVASCULAR DISEASES, 2004, 17 (2-3) :182-190
[2]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[3]   Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].
Barber, PA ;
Zhang, J ;
Demchuk, AM ;
Hill, MD ;
Buchan, AM .
NEUROLOGY, 2001, 56 (08) :1015-1020
[4]   Thrombolytic therapy of acute basilar artery occlusion - Variables affecting recanalization and outcome [J].
Brandt, T ;
vonKummer, R ;
MullerKuppers, M ;
Hacke, W .
STROKE, 1996, 27 (05) :875-881
[5]   Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2109-2118
[6]   Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2119-2125
[7]   Prehospital delay after acute stroke in Kaohsiung, Taiwan [J].
Chang, KC ;
Tseng, MC ;
Tan, TY .
STROKE, 2004, 35 (03) :700-704
[8]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[9]   Reasons for exclusion from thrombolytic therapy following acute ischemic stroke [J].
Cocho, D ;
Belvís, R ;
Martí-Fàbregas, J ;
Molina-Porcel, L ;
Díaz-Manera, J ;
Aleu, A ;
Pagonabarraga, J ;
García-Bargo, D ;
Mauri, A ;
Martí-Vilalta, JL .
NEUROLOGY, 2005, 64 (04) :719-720
[10]   Predictors of good outcome after intravenous tPA for acute ischemic stroke [J].
Demchuk, AM ;
Tanne, D ;
Hill, MD ;
Kasner, SE ;
Hanson, S ;
Grond, M ;
Levine, SR .
NEUROLOGY, 2001, 57 (03) :474-480